Given the multifactorial nature of cachexia, encompassing muscle atrophy, lipolysis, anorexia, and chronic inflammation, PPARγ agonists offer a mechanistically diverse therapeutic strategy that targets several hallmarks of this syndrome (Table 2). Here, PPARG is linked to Cachexia.